{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:59:40Z","timestamp":1792879180593,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"abbvie inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12325-021-01928-y","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T03:32:18Z","timestamp":1635305538000},"page":"5777-5790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017\u20132019"],"prefix":"10.1007","volume":"38","author":[{"given":"Nancy","family":"Reau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji R.","family":"Manthena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Chirikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Dylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana M.","family":"Carabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"1928_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156:431\u201345.","journal-title":"Gastroenterology"},{"key":"1928_CR2","first-page":"e224","volume":"22","author":"X Yao","year":"2016","unstructured":"Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010\u20132014. Am J Manag Care. 2016;22:e224\u201332.","journal-title":"Am J Manag Care"},{"key":"1928_CR3","doi-asserted-by":"crossref","unstructured":"Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1:e186371.","DOI":"10.1001\/jamanetworkopen.2018.6371"},{"key":"1928_CR4","unstructured":"Reau N, Marx S, Manthena S, Strezewski J, Chirikov V. National examination of HCV linkage to care in the United States (2013-2016) based on large real-world dataset. Poster presentation at The Liver Meeting\u00ae 2018, November 09\u201313, 2018, San Francisco, CA, USA"},{"key":"1928_CR5","unstructured":"Sulkowski M, Marx S, Manthena S, Strezewski J, Chirikov V. National estimates for HCV screening and diagnosis rates in the United States (2013-2016) based on large real-world dataset. Poster presentation at The Liver Meeting\u00ae 2018, November 09\u201313, 2018, San Francisco, CA, USA"},{"key":"1928_CR6","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV testing and linkage to care. Page last updated August 27, 2020. https:\/\/www.hcvguidelines.org\/evaluate\/testing-and-linkage. Accessed January 26, 2021."},{"key":"1928_CR7","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report - United States, 2019. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm. Published May 2021. Accessed June 30, 2021."},{"key":"1928_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","volume":"69","author":"AB Ryerson","year":"2020","unstructured":"Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases\u2013United States, 2009\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69:399\u2013404.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1928_CR9","unstructured":"Centers for Disease Control and Prevention. Testing recommendations for hepatitis C virus infection. Page last reviewed July 29, 2020. (https:\/\/www.cdc.gov\/hepatitis\/hcv\/guidelinesc.htm#:~:text=CDC%20Recommendations%20for%20Hepatitis%20C,is%20less%20than%200.1%25*). Accessed January 7, 2021."},{"key":"1928_CR10","unstructured":"Force USPST, Owens DK, Davidson KW, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020."},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cld.915","volume":"16","author":"DL Thomas","year":"2020","unstructured":"Thomas DL. State of the hepatitis C virus care cascade. Clin Liver Dis. 2020;16:8\u201311.","journal-title":"Clin Liver Dis"},{"key":"1928_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s12325-018-0721-1","volume":"35","author":"VV Chirikov","year":"2018","unstructured":"Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a comprehensive dataset of hepatitis C patients and examination of disease epidemiology in the United States, 2013\u20132016. Adv Ther. 2018;35:1087\u2013102.","journal-title":"Adv Ther"},{"key":"1928_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1928_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","volume":"12","author":"AS Perelson","year":"2015","unstructured":"Perelson AS, Guedj J. Modelling hepatitis C therapy\u2013predicting effects of treatment. Nat Rev Gastroenterol Hepatol. 2015;12:437\u201345.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1928_CR15","unstructured":"Centers for Disease Control and Prevention. People who use or inject drugs and viral hepatitis. Page last reviewed August 24, 2020."},{"key":"1928_CR16","doi-asserted-by":"crossref","unstructured":"Bradley H, Hall EW, Rosenthal EM, Sullivan PS, Ryerson AB, Rosenberg ES. Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013\u20132016. Hepatol Commun. 2020;4:355\u201370.","DOI":"10.1002\/hep4.1457"},{"key":"1928_CR17","doi-asserted-by":"crossref","unstructured":"Islam JY, Spees L, Camacho-Rivera M, Vidot DC, Yarosh R, Wheldon CW. Disparities in awareness of hepatitis C virus among U.S. adults: an analysis of the 2019 Health Information National Trends Survey. Sex Transm Dis. 2021.","DOI":"10.1097\/OLQ.0000000000001478"},{"key":"1928_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1665-2681(19)30758-6","volume":"14","author":"LE Mu\u00f1oz-Espinosa","year":"2015","unstructured":"Mu\u00f1oz-Espinosa LE, Trujillo-Trujillo ME, Mart\u00ednez-Mac\u00edas RF, et al. Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals Hepatol. 2015;14:642\u201351.","journal-title":"Annals Hepatol."},{"key":"1928_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/apt.12646","volume":"39","author":"J Ampuero","year":"2014","unstructured":"Ampuero J, Romero-G\u00f3mez M, Reddy KR. Review article: HCV genotype 3 \u2013 the new treatment challenge. Alimentary Pharmacol Ther. 2014;39:686\u201398.","journal-title":"Alimentary Pharmacol Ther."},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1469-0691.2004.00934.x","volume":"10","author":"J Harder","year":"2004","unstructured":"Harder J, Walter E, Riecken B, Ihling C, Bauer TM. Hepatitis C virus infection in intravenous drug users. Clin Microbiol Infect. 2004;10:768\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"1928_CR21","unstructured":"WHO. Global health sector strategy on viral hepatitis 2016\u20132021; 2020. https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/. Accessed January 27, 2021."},{"key":"1928_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep4.1673","volume":"5","author":"JM Paik","year":"2021","unstructured":"Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The growing burden of disability related to chronic liver disease in the United States: Data From the Global Burden of Disease Study 2007\u20132017. Hepatol Commun. 2021;5:749\u201359.","journal-title":"Hepatol Commun"},{"key":"1928_CR23","doi-asserted-by":"crossref","unstructured":"Gowda C, Lott S, Grigorian M, et al. Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study. Open Forum Infect Dis. 2018;5:ofy076.","DOI":"10.1093\/ofid\/ofy076"},{"key":"1928_CR24","unstructured":"Waters P, Greenwald R, Ninburg M, Simmons State policies limiting progress towards HCV elimination in the U.S.. Poster presentation at The Liver Meeting\u00ae 2020, November 13\u201316, 2020, Virtual."},{"key":"1928_CR25","unstructured":"Access HCSoM. Hepatitis C: state of Medicaid access; 2020. stateofhepc.org. Accessed March 17, 2020 2020."},{"key":"1928_CR26","unstructured":"National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation of Harvard Law School. Hepatitis C: State of Medicaid Access. Updated May 2021. http:\/\/stateofhepc.org\/wp-content\/uploads\/2021\/05\/HCV_State-of-Medicaid-Access_May-2021-Progress-Report.pdf. Accessed June 2, 2021."},{"key":"1928_CR27","unstructured":"National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation of Harvard Law School. Hepatitis C: State of Medicaid Access. Discriminatory State Medicaid Restrictions. Updated October 2019. https:\/\/stateofhepc.org\/report\/. Accessed January 27, 2021."},{"key":"1928_CR28","unstructured":"National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation of Harvard Law School. Hepatitis c: The State of Medicaid Access\u2014Inforgraphic: See how your state matches up. https:\/\/stateofhepc.org\/resources\/. Accessed January 27, 2021."},{"key":"1928_CR29","doi-asserted-by":"publisher","first-page":"44S","DOI":"10.1177\/0033354920904608","volume":"135","author":"R Greenwald","year":"2020","unstructured":"Greenwald R, Waters P, Cayer S. Enforcement of legal remedies to secure hepatitis C virus treatment with direct-acting antiviral therapies in correctional facilities and Medicaid programs. Public Health Rep. 2020;135:44S-S49.","journal-title":"Public Health Rep"},{"key":"1928_CR30","unstructured":"MappingHepC. Interactive map; 2020. https:\/\/mappinghepc.com\/maps. Accessed June 2 2021."},{"key":"1928_CR31","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2018.15782","volume":"320","author":"MR Trusheim","year":"2018","unstructured":"Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis C treatment\u2014The \u201cNetflix Model.\u201d JAMA. 2018;320:1977\u20138.","journal-title":"JAMA"},{"key":"1928_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31\u20136.","journal-title":"J Hepatol"},{"key":"1928_CR33","unstructured":"Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm Accessed July 1, 2021."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01928-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T19:12:33Z","timestamp":1636225953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01928-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}